Biotech Stock Nanobiotix (NBTX) Is Up 660% This Year -- Here's Why the Rally Could Continue

NANO.PA +4.29% JNJ +0.77%

Key Points

• Nanobiotix is a small French biotechnology company.

• It has secured financing from Johnson & Johnson and elsewhere.

• It's not a no-brainer investment, but it might do well.

• 10 stocks we like better than Nanobiotix ›

Nanobiotix (NASDAQ: NBTX) is a French biotechnology stock, and one that has soared 660% in 2025 as of Nov. 18. That's enough to draw investor attention, and to have many wondering if such torrid growth could continue. Well, it could -- because the company has some deep pockets behind it. But it might not. Let's take a closer look.

In its own words: "Nanobiotix is a late-stage clinical biotechnology company pioneering the discovery, development, manufacture, and commercialization of disruptive, physics-based nanotherapeutics. We aim to create products that will transform health outcomes for millions of people with cancer and other challenging diseases."

That certainly sounds positive and promising. But consider these factors before you devote any dollars to the stock:

• Like many biotechnology companies, it's developing drugs more than actually selling them. It raked in negligible revenue until 2023, when it took in $30 million, and its current run rate is a bit below that.

• Its market capitalization of $1 billion makes it a small-cap stock, and those can be more volatile than larger ones.

On the other hand:

• It needs cash to continue its work, and it recently secured up to $71 million via a royalty-based agreement with investment firm Healthcare Royalty Partners (now controlled by the private equity company KKR). What's especially nice about this deal is that it's not dilutive to existing shareholders. Had Nanobiotix simply issued more shares, that would have diluted the value of existing shares.

• It has a promising cancer-fighting drug in development, and has a licensing deal with Johnson & Johnson for it. It's common for biotech companies to partner with deep-pocketed big pharma companies in order to get drugs to market, and this shows that J&J is a believer in Nanobiotix.

So -- will its growth continue? It might, but much depends on how well it uses its cash and how effectively it secures more cash when needed. I wouldn't park much of my money in it, but you might consider investing a small sum -- especially if you're savvy about biotechnology and have studied the company.

Should you buy stock in Nanobiotix right now?

Before you buy stock in Nanobiotix, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Nanobiotix wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $562,536!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,096,510!*

Now, it’s worth noting Stock Advisor’s total average return is 981% — a market-crushing outperformance compared to 187% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.

See the 10 stocks »

*Stock Advisor returns as of November 24, 2025

Selena Maranjian has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends KKR. The Motley Fool recommends Johnson & Johnson. The Motley Fool has a disclosure policy.

Biotech Stock Nanobiotix (NBTX) Is Up 660% This Year -- Here's Why the Rally Could Continue was originally published by The Motley Fool